Taysha Gene Therapies (TSHA) stock price, revenue, and financials
Taysha Gene Therapies market cap is $106.6 m.
$2.68
$106.6 M
TSHA Mkt cap, 20-May-2022Taysha Gene Therapies Net income (FY, 2020)-60 M
Taysha Gene Therapies EBIT (FY, 2020)-43 M
Taysha Gene Therapies Cash, 31-Dec-2020251.3 M
Taysha Gene Therapies Income Statement
Annual
Taysha Gene Therapies Balance Sheet
Annual
| USD | FY, 2019 | FY, 2020 |
|---|---|---|
Cash | 251.3m | |
Prepaid Expenses | 6.6m | |
Current Assets | 15.0k | 257.9m |
PP&E | 287.0k | |
Total Assets | 15.0k | 258.9m |
Accounts Payable | 2.0m | |
Current Liabilities | 150.0k | 7.1m |
Total Liabilities | 150.0k | 7.6m |
Additional Paid-in Capital | 980.0k | 312.4m |
Retained Earnings | (1.1m) | (61.1m) |
Total Equity | (135.0k) | 251.3m |
Financial Leverage | -0.1 x | 1 x |
Quarterly
| USD | Q2, 2020 | Q3, 2020 |
|---|---|---|
Cash | 11.2m | 278.6m |
Prepaid Expenses | 9.0k | 604.0k |
Current Assets | 11.3m | 279.2m |
PP&E | 19.0k | 28.0k |
Total Assets | 11.3m | 279.3m |
Accounts Payable | 1.3m | 8.8m |
Current Liabilities | 20.1m | 11.6m |
Total Liabilities | 20.1m | 11.6m |
Preferred Stock | 18.0m | |
Additional Paid-in Capital | 980.0k | 310.5m |
Retained Earnings | (27.8m) | (42.8m) |
Total Equity | (26.8m) | 267.6m |
Financial Leverage | -0.4 x | 1 x |
Taysha Gene Therapies Cash Flow
Annual
Quarterly
| USD | Q2, 2020 | Q3, 2020 |
|---|---|---|
Net Income | (26.7m) | (41.7m) |
Depreciation and Amortization | 3.0k | |
Accounts Payable | 1.2m | 5.4m |
Cash From Operating Activities | (4.2m) | (10.9m) |
Purchases of PP&E | (31.0k) | |
Cash From Investing Activities | (3.0m) | (3.0m) |
Cash From Financing Activities | 18.4m | 292.5m |
Net Change in Cash | 11.2m | 278.6m |
Interest Paid | 27.0k | 28.0k |
Taysha Gene Therapies Ratios
| USD | FY, 2019 |
|---|---|
Financial Leverage | -0.1 x |
